Risk factors for unplanned readmission after transjugular intrahepatic portosystemic shunt in cirrhotic patients with esophagogastric variceal bleeding and construction of a nomogram model

Qin YIN; Zhaorong WU; Feng ZHANG; Chunyan JIN; Yanping CAO; Jiangqiang XIAO; Yuzheng ZHUGE; Qian WANG

doi:10.12449/JCH240913

Volume 40 Issue 9

Sep. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(9): 1796-1801

PDF( 1108 KB)

Risk factors for unplanned readmission after transjugular intrahepatic portosystemic shunt in cirrhotic patients with esophagogastric variceal bleeding and construction of a nomogram model

DOI: 10.12449/JCH240913

Department of Gastroenterology，Affiliated Drum Tower Hospital of Nanjing University Medical School，Nanjing 210008，China

Research funding:

National Natural Science Found of China (82100652);

Affiliated Drum Tower Hospital of Nanjing University Medical School Nursing Research Project (ZSA796-1)

More Information

Corresponding author: WANG Qian， 523199780@qq.com （ORCID： 0009-0003-8598-1169）
Received Date: 2024-01-15
Accepted Date: 2024-04-11
Published Date: 2024-09-25

Abstract

Abstract

Objective To investigate the risk factors for unplanned readmission within 30 days after discharge in cirrhotic patients with esophagogastric variceal bleeding undergoing transjugular intrahepatic portosystemic shunt （TIPS）， and to construct a nomogram predictive model. Methods A total of 241 cirrhotic patients who underwent TIPS due to esophagogastric variceal bleeding in Affiliated Drum Tower Hospital of Nanjing University Medical School from January 2020 to June 2023 were enrolled as subjects， and unplanned readmission within 30 days was analyzed. According to the presence or absence of unplanned readmission， they were divided into readmission group with 36 patients and non-readmission group with 198 patients， and related clinical data were collected from all patients. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between two groups. A logistic regression analysis was used to identify independent risk factors for unplanned readmission. A nomogram prediction model was constructed， and the receiver operating characteristic （ROC） curve was plotted to assess its discriminatory ability for unplanned readmission； the calibration curve was plotted to evaluate the consistency of the nomogram model in predicting unplanned readmission； the ResourceSelection package of R language was used for the Hosmer-Lemeshow goodness-of-fit test to evaluate the degree of fitting of the mode； the decision curve analysis was used to investigate the practicality of the model. Results Age （odds ratio ［OR］=2.664， 95% confidence interval ［CI］： 1.139‍ ‍—‍ ‍6.233， P<0.05）， CTP score （OR=1.655， 95%CI： 1.098‍ ‍—‍ ‍2.495， P<0.05）， and blood ammonia （OR=1.032， 95%CI： 1.016‍ ‍—‍ ‍1.048， P<0.05） were independent risk factors for unplanned readmission within 30 days after discharge in the patients undergoing TIPS. The multivariate analysis showed that for the nomogram predictive model constructed in this study， repeated sampling for 1 000 times using the Bootstrap method was performed for internal validation， and the area under the ROC curve was 0.773， which was significantly higher than that of age （0.582）， CTP score （0.675）， and blood ammonia （0.641）. The calibration curve showed good consistency between the probability of unplanned readmission predicted by the nomogram model and the actual probability， and the Hosmer-Lemeshow goodness-of-fit test showed good degree of fitting （c² =5.647 3， P=0.686 7）. Conclusion Age， CTP score， and blood ammonia are independent risk factors for unplanned readmission within 30 days after TIPS， and the nomogram prediction model constructed based on these factors can help to predict the risk of unplanned readmission in TIPS patients and provide an accurate decision-making basis for early prevention.
- Liver Cirrhosis,
- Portasystemic Shunt， Transjugular Intrahepatic,
- Risk Factors

FullText(HTML)

References(23)

References

[1]	BOIKE JR, THORNBURG BG, ASRANI SK, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20( 8): 1636- 1662. e 36. DOI: 10.1016/j.cgh.2021.07.018.
[2]	de FRANCHIS R, BAVENO VI FACULTY. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63( 3): 743- 752. DOI: 10.1016/j.jhep.2015.05.022.
[3]	LYU Y, FAN DM, HAN GH. Application status and future prospect of transjugular intrahepatic portosystemic shunt in gastroesophageal variceal bleeding in liver cirrhosis[J]. J Clin Hepatol, 2022, 38( 6): 1229- 1233. DOI: 10.3969/j.issn.1001-5256.2022.06.004. 吕勇, 樊代明, 韩国宏. 经颈静脉肝内门体分流术在肝硬化食管胃底静脉曲张破裂出血中的应用现状与未来展望[J]. 临床肝胆病杂志, 2022, 38( 6): 1229- 1233. DOI: 10.3969/j.issn.1001-5256.2022.06.004.
[4]	ZHANG K, LIU JL, LIU YL, et al. To observe the clinical effect of transjugular intrahepatic portosystemic shunt guided by 3D model constructed by CT thin-layer scanning data computer in the treatment of cirrhotic portal hypertension complicated with gastrointestinal bleeding[J]. Clin J Med Offic, 2023, 51( 6): 655- 656, 660. DOI: 10.16680/j.1671-3826.2023.06.28. 张凯, 刘晶磊, 刘燚隆, 等. 应用CT薄层扫描数据电脑构建3D模型指导经颈静脉肝内门体分流术治疗肝硬化门脉高压合并消化道出血临床效果观察[J]. 临床军医杂志, 2023, 51( 6): 655- 656, 660. DOI: 10.16680/j.1671-3826.2023.06.28.
[5]	CHEN GH, WANG GC, ZHANG CQ. Current status of research on hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol, 2021, 37( 5): 1201- 1204. DOI: 10.3969/j.issn.1001-5256.2021.05.047. 陈功海, 王广川, 张春清. 经颈静脉肝内门体分流术后肝性脑病的研究现状[J]. 临床肝胆病杂志, 2021, 37( 5): 1201- 1204. DOI: 10.3969/j.issn.1001-5256.2021.05.047.
[6]	FENG LJ, WANG Y, JIA JD. Clinical management of common complications of liver cirrhosis[J]. Chin Hepatol, 2023, 28( 1): 13- 16. DOI: 10.14000/j.cnki.issn.1008-1704.2023.01.033. 冯丽娟, 王宇, 贾继东. 肝硬化常见并发症的临床管理[J]. 肝脏, 2023, 28( 1): 13- 16. DOI: 10.14000/j.cnki.issn.1008-1704.2023.01.033.
[7]	The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension(2019 edition)[J]. J Clin Hepatol, 2019, 35( 12): 2694- 2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2694- 2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
[8]	ZHOU NS, ZHANG J, MA XM, et al. The study of unplanned readmission within 31 days after being discharged in one general third-level grade A hospital in Beijing[J]. Chin Hosp Manag, 2010, 30( 4): 18- 20. DOI: 10.3969/j.issn.1001-5329.2010.04.008. 周念松, 张俊, 马谢民, 等. 北京市某三甲医院31天内非计划性再入院研究[J]. 中国医院管理, 2010, 30( 4): 18- 20. DOI: 10.3969/j.issn.1001-5329.2010.04.008.
[9]	General Office of the Ministry of Health. Notice on printing and distributing the indicators of medical quality management and control in tertiary general hospitals(2011 edition)[EB/OL].( 2011-01-27)[ 2023-11-10]. http://www.gov.cn/gzdt/2011-01/27/content_1793358.htm. http://www.gov.cn/gzdt/2011-01/27/content_1793358.htm 卫生部办公厅. 关于印发《三级综合医院医疗质量管理与控制指标(2011年版)》的通知[EB/OL].( 2011-01-27)[ 2023-11-10]. http://www.gov.cn/gzdt/2011-01/27/content_1793358.htm. http://www.gov.cn/gzdt/2011-01/27/content_1793358.htm
[10]	HAN Q. Analysis of types of diseases, days of interval and influencing factors of unplanned re-admission patients within 31 days after discharge[J]. Chin Nurs Res, 2020, 34( 16): 2862- 2867. DOI: 10.12102/j.issn.1009-6493.2020.16.010. 韩祺. 出院31 d内非计划再入院病人疾病种类、间隔天数与影响因素分析[J]. 护理研究, 2020, 34( 16): 2862- 2867. DOI: 10.12102/j.issn.1009-6493.2020.16.010.
[11]	SARWAR A, WEINSTEIN JL, NOVACK V, et al. Causes and rates of 30-day readmissions after transjugular intrahepatic portosystemic shunts[J]. AJR Am J Roentgenol, 2020, 215( 1): 235- 241. DOI: 10.2214/AJR.19.21732.
[12]	SHENG S, HUANG Y. Establishment and validation of the interactive nomogram model for all-cause readmission within 90-days in patients with heart failure[J]. Chin J Integr Med Cardio Cerebrovasc Dis, 2023, 21( 16): 2909- 2915. DOI: 10.12102/j.issn.1672-1349.2023.16.002. 盛松, 黄烨. 心力衰竭病人90 d内再入院的交互式列线图模型建立与验证[J]. 中西医结合心脑血管病杂志, 2023, 21( 16): 2909- 2915. DOI: 10.12102/j.issn.1672-1349.2023.16.002.
[13]	CHEN XY, LI K, WANG X, et al. Establishment of prediction model of unplanned readmission within 30 days after discharge in elderly patients receiving total knee arthroplasty[J]. Pract Geriatr, 2023, 37( 8): 772- 776. DOI: 10.3969/j.issn.1003-9198.2023.08.005. 陈翔宇, 李凯, 王旭, 等. 老年病人行全膝关节置换术出院后30天内非计划再入院预测模型的建立[J]. 实用老年医学, 2023, 37( 8): 772- 776. DOI: 10.3969/j.issn.1003-9198.2023.08.005.
[14]	MA L, WANG ZX, LUO B. Predictive value of HALP index for unplanned readmission within 30 days after discharge in elderly patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Pract J Card Cereb Pneumal Vasc Dis, 2024, 32( 2): 20- 23. DOI: 10.12114/j.issn.1008-5971.2024.00.028. 马玲, 王志贤, 罗兵. HALP指数对老年慢性阻塞性肺疾病急性加重期患者出院后30 d内非计划再入院的预测价值[J]. 实用心脑肺血管病杂志, 2024, 32( 2): 20- 23. DOI: 10.12114/j.issn.1008-5971.2024.00.028.
[15]	ZHANG JQ, WANG ZC, YANG JY, et al. Construction and validation of the risk prediction model for secondary hepatic encephalopathy in patients with chronic hepatitis B and cirrhosis[J]. Chin Hepatol, 2023, 28( 8): 916- 920, 931. DOI: 10.14000/j.cnki.issn.1008-1704.2023.08.011. 张家齐, 王再超, 杨家耀, 等. 慢性乙型肝炎肝硬化患者继发肝性脑病风险预测模型的构建与验证[J]. 肝脏, 2023, 28( 8): 916- 920, 931. DOI: 10.14000/j.cnki.issn.1008-1704.2023.08.011.
[16]	PUGH RN, MURRAY-LYON IM, DAWSON JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60( 8): 646- 649. DOI: 10.1002/bjs.1800600817.
[17]	LI H, XIA ZB, XIAO NJ, et al. Current research status of prognostic models for transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol, 2023, 39( 5): 1191- 1196. DOI: 10.3969/j.issn.1001-5256.2023.05.030. 李慧, 夏志波, 肖年军, 等. 经颈静脉肝内门体分流术预后模型的研究现状[J]. 临床肝胆病杂志, 2023, 39( 5): 1191- 1196. DOI: 10.3969/j.issn.1001-5256.2023.05.030.
[18]	LIU ZL, FAN ZP, LIU YL, et al. Value of Model for End-Stage Liver Disease and Child-Turcotte-Pugh score in predicting the prognosis of patients with hepatic sinus obstruction syndrome associated with Gynura segetum(Lour.) Merr[J]. J Clin Hepatol, 2020, 36( 11): 2462- 2466. DOI: 10.3969/j.issn.1001-5256.2020.11.013. 刘贞利, 范作鹏, 柳雅立, 等. 终末期肝病模型及CTP评分系统对土三七相关肝窦阻塞综合征患者预后的预测价值[J]. 临床肝胆病杂志, 2020, 36( 11): 2462- 2466. DOI: 10.3969/j.issn.1001-5256.2020.11.013.
[19]	ZHANG F, LIU B, SHI YQ, et al. Analysis of risk factors for hepatic encephalopathy in patients with liver cirrhosis with upper gastrointestinal bleeding[J]. Chin J Integr Tradit West Med Dig, 2018, 26( 11): 934- 937. DOI: 10.3969/j.issn.1671-038X.2018.11.10. 张飞, 刘斌, 施彦卿, 等. 肝硬化上消化道出血患者并发肝性脑病的危险因素分析[J]. 中国中西医结合消化杂志, 2018, 26( 11): 934- 937. DOI: 10.3969/j.issn.1671-038X.2018.11.10.
[20]	LOCKWOOD AH. Blood ammonia levels and hepatic encephalopathy[J]. Metab Brain Dis, 2004, 19( 3-4): 345- 349. DOI: 10.1023/b: mebr.0000043980.74574.eb.
[21]	VILSTRUP H, AMODIO P, BAJAJ J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J]. Hepatology, 2014, 60( 2): 715- 735. DOI: 10.1002/hep.27210.
[22]	BROWN JR, ALONSO A, MAZIMBA S, et al. Improved 30 day heart failure rehospitalization prediction through the addition of device-measured parameters[J]. ESC Heart Failure, 2020, 7( 6): 3762- 3771. DOI: 10.1002/ehf2.12956.
[23]	GLANCE LG, KELLERMANN AL, OSLER TM, et al. Hospital readmission after noncardiac surgery: the role of major complications[J]. JAMA Surg, 2014, 149( 5): 439- 445. DOI: 10.1001/jamasurg.2014.4.

Relative Articles

[1]	Wenting CHAO, Rui HUANG. Diagnosis and treatment of decompensated cirrhosis with multiple primary cancers： A case report[J]. Journal of Clinical Hepatology, 2024, 40(9): 1868-1872. doi: 10.12449/JCH240923
[2]	Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
[3]	Xinyi LI, Jiaojiao LI, Wei SUN. Establishment and evaluation of a nomogram prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis and esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2024, 40(8): 1605-1611. doi: 10.12449/JCH240816
[4]	Lanjing WANG, Jianping QIN, Xin YAO, Qi QI, Lin LIU, Shanhong TANG. Construction of a risk prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatitis B cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2024, 40(6): 1149-1155. doi: 10.12449/JCH240613
[5]	Xiang GAO, Xiaofeng ZHANG, Yimin CAO, Jinjun CHEN, Xiaoqin LUO. Efficacy of transjugular intrahepatic portosystemic shunt in treatment of hepatocellular carcinoma comorbid with esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2024, 40(10): 2027-2033. doi: 10.12449/JCH241016
[6]	Tianfu LIU, Liang WANG, Lingyi ZHANG. Risk factors for non－neoplastic portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(9): 2122-2127. doi: 10.3969/j.issn.1001-5256.2023.09.014
[7]	Henglu BIAN, Jiasu LI, Cui LIU, Feng LIU. An excerpt of AASLD practice guidance on the use of TIPS， variceal embolization， and retrograde transvenous obliteration in the management of variceal hemorrhage in 2023[J]. Journal of Clinical Hepatology, 2023, 39(11): 2564-2568. doi: 10.3969/j.issn.1001-5256.2023.11.008
[8]	Qiong WU, Lianhui ZHAO, Guangchuan WANG, Chunqing ZHANG. Transjugular intrahepatic portosystemic shunt combined with collateral vessel embolization in treatment of gastroesophageal variceal bleeding in liver cirrhosis： Research advances and controversies[J]. Journal of Clinical Hepatology, 2023, 39(10): 2460-2463. doi: 10.3969/j.issn.1001-5256.2023.10.026
[9]	Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020
[10]	Shanshan LI, Manman XU, Zhongping DUAN, Yu CHEN. Risk factors for liver cirrhosis in acute-on-chronic liver failure patients without liver cirrhosis in the convalescence stage[J]. Journal of Clinical Hepatology, 2021, 37(12): 2824-2829. doi: 10.3969/j.issn.1001-5256.2021.12.019
[11]	LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003
[12]	Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043
[13]	Lyu Jing, Dong SiSi, Gu HongTu, Zhao ZhangQing, Liu ChengHai. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2210-2213. doi: 10.3969/j.issn.1001-5256.2019.10.016
[14]	He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041
[15]	Jin Yan, Wang Xue, Zhang LingJuan, Qiu Ting, Shang BoXin, Lian XiaoYan, Yan ChunYing, Duan TianJiao, Zhang Rong, Liu GuiSheng. Risk factors for early rebleeding after esophageal variceal ligation in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2147-2151. doi: 10.3969/j.issn.1001-5256.2017.11.019
[16]	Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(2): 275-278. doi: 10.3969/j.issn.1001-5256.2016.02.015
[17]	Yang Hua, Liu YunXia, Li Peng, Yang ShaoQi, Wang YuanZhen. Analysis of risk factors for early rebleeding from esophageal and gastric varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(6): 540-542. doi: 10.3969/j.issn.1001-5256.2014.06.015
[18]	Gu Chuan, Li Lu, Wang Jun, Hou FengQin, Xu XiaoYuan. Study on efficacy of endoscopic ligation therapy for esophageal varices and risk factors for postoperative rebleeding[J]. Journal of Clinical Hepatology, 2014, 30(12): 1279-1282. doi: 10.3969/j.issn.1001-5256.2014.12.011
[19]	Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	陈刚，谷光丽，何映雪，唐尧. 血清表皮生长因子对肝硬化食管胃静脉曲张患者再出血的诊断价值分析. 转化医学杂志. 2024(10): 1698-1702 .
2.	梅蓉，蒋成，解维婷. 原发性肝癌切除术后复发患者肠道和舌苔菌群变化特征及相关性分析. 转化医学杂志. 2024(10): 1685-1688 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (254) PDF downloads(32)